Jpmorgan Chase & CO Eye Point Pharmaceuticals, Inc. Transaction History
Jpmorgan Chase & CO
- $1.1 Trillion
- Q1 2024
A detailed history of Jpmorgan Chase & CO transactions in Eye Point Pharmaceuticals, Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 27,621 shares of EYPT stock, worth $240,302. This represents 0.0% of its overall portfolio holdings.
Number of Shares
27,621
Previous 24,665
11.98%
Holding current value
$240,302
Previous $570,000
-0.0%
% of portfolio
0.0%
Previous 0.0%
Shares
12 transactions
Others Institutions Holding EYPT
# of Institutions
176Shares Held
53.9MCall Options Held
764KPut Options Held
1.57M-
Cormorant Asset Management, LP Boston, MA6.89MShares$60 Million8.2% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA4.76MShares$41.4 Million0.19% of portfolio
-
Suvretta Capital Management, LLC New York, NY3.76MShares$32.7 Million3.33% of portfolio
-
Franklin Resources Inc San Mateo, CA3.39MShares$29.5 Million0.02% of portfolio
-
Black Rock Inc. New York, NY2.79MShares$24.3 Million0.0% of portfolio
About EyePoint Pharmaceuticals, Inc.
- Ticker EYPT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 34,072,200
- Market Cap $296M
- Description
- EyePoint Pharmaceuticals, Inc., a pharmaceutical company, develops and commercializes ophthalmic products for the treatment of eye diseases in the United States, China, and the United Kingdom. The company provides ILUVIEN, an injectable sustained-release micro-insert for treatment of diabetic macular edema; YUTIQ, a fluocinolone acetonide intrav...